MX2022004779A - Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. - Google Patents

Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.

Info

Publication number
MX2022004779A
MX2022004779A MX2022004779A MX2022004779A MX2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A
Authority
MX
Mexico
Prior art keywords
glp
receptor agonists
dementia
semaglutide
subjects
Prior art date
Application number
MX2022004779A
Other languages
English (en)
Inventor
Sarah Friedrich
Charlotte Christine Thim Hansen
Lotte Bjerre Knudsen
Anna Secher
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022004779A publication Critical patent/MX2022004779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a terapias médicas mejoradas para todas las formas y etapas de demencia que implican la administración de (i) agonistas del receptor de GLP-1 a sujetos con síndrome metabólico o (ii) semaglutida.
MX2022004779A 2019-11-06 2020-11-05 Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. MX2022004779A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP20186623 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Publications (1)

Publication Number Publication Date
MX2022004779A true MX2022004779A (es) 2022-06-14

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004779A MX2022004779A (es) 2019-11-06 2020-11-05 Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.

Country Status (12)

Country Link
US (3) US20220280612A1 (es)
EP (1) EP4054620B1 (es)
JP (1) JP2023500032A (es)
KR (1) KR20220110731A (es)
CN (1) CN114728042A (es)
AU (1) AU2020377469A1 (es)
BR (1) BR112022007721A2 (es)
CA (1) CA3154744A1 (es)
IL (1) IL291876A (es)
MX (1) MX2022004779A (es)
TW (1) TW202118509A (es)
WO (1) WO2021089678A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도
JP2024500410A (ja) * 2020-12-16 2024-01-09 ザ チャイニーズ ユニバーシティー オブ ホンコン 老化脳機能低下を逆転する方法
AU2022400245A1 (en) 2021-12-02 2024-05-30 Københavns Universitet Peptide-drug conjugates for treatment of neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US7544833B2 (en) 2006-09-07 2009-06-09 Hoffmann-La Roche Inc. Methods for producing N-(8-[2-hydroxybenzoyl]-amino) caprylic acid
CN102791731B (zh) 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 Glp-1类似物和衍生物
RS56998B1 (sr) * 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
WO2012140117A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
CA2877056A1 (en) * 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
JP6768515B2 (ja) 2014-04-07 2020-10-14 ノヴォ ノルディスク アー／エス 二重アシル化ｇｌｐ−１化合物
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
US11123405B2 (en) * 2015-12-23 2021-09-21 The Johns Hopkins University Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use

Also Published As

Publication number Publication date
JP2023500032A (ja) 2023-01-04
WO2021089678A1 (en) 2021-05-14
TW202118509A (zh) 2021-05-16
EP4054620B1 (en) 2024-05-29
US20230302094A1 (en) 2023-09-28
US20220280612A1 (en) 2022-09-08
US20240207364A1 (en) 2024-06-27
BR112022007721A2 (pt) 2022-07-12
IL291876A (en) 2022-06-01
CN114728042A (zh) 2022-07-08
CA3154744A1 (en) 2021-05-14
EP4054620C0 (en) 2024-05-29
KR20220110731A (ko) 2022-08-09
AU2020377469A1 (en) 2022-04-28
EP4054620A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MX2022004779A (es) Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2020010689A (es) Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2021005382A (es) Vehiculos derivados de cholix para suministro oral de carga util heterologa.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
GB201201314D0 (en) Composition
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
MX2018002000A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
PH12021551540A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2018001849A (es) Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
MX2018012800A (es) Administracion de metabolitos de berberina.